JP2018519803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519803A5 JP2018519803A5 JP2017560331A JP2017560331A JP2018519803A5 JP 2018519803 A5 JP2018519803 A5 JP 2018519803A5 JP 2017560331 A JP2017560331 A JP 2017560331A JP 2017560331 A JP2017560331 A JP 2017560331A JP 2018519803 A5 JP2018519803 A5 JP 2018519803A5
- Authority
- JP
- Japan
- Prior art keywords
- ser
- arg
- tyr
- leu
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167927.1 | 2015-05-18 | ||
| EP15167927 | 2015-05-18 | ||
| EP16150508 | 2016-01-08 | ||
| EP16150508.6 | 2016-01-08 | ||
| PCT/EP2016/061071 WO2016184882A1 (en) | 2015-05-18 | 2016-05-18 | Anti-cancer fusion polypeptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519803A JP2018519803A (ja) | 2018-07-26 |
| JP2018519803A5 true JP2018519803A5 (enExample) | 2019-06-20 |
| JP6947642B2 JP6947642B2 (ja) | 2021-10-13 |
Family
ID=56134305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560331A Active JP6947642B2 (ja) | 2015-05-18 | 2016-05-18 | 抗がん性融合ポリペプチド |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10913778B2 (enExample) |
| EP (2) | EP3298030B1 (enExample) |
| JP (1) | JP6947642B2 (enExample) |
| KR (1) | KR102685748B1 (enExample) |
| CN (1) | CN108112253B (enExample) |
| AU (1) | AU2016262845B2 (enExample) |
| CA (1) | CA2980838A1 (enExample) |
| DK (1) | DK3298030T5 (enExample) |
| ES (1) | ES2938525T3 (enExample) |
| FI (1) | FI3298030T3 (enExample) |
| HR (1) | HRP20230145T1 (enExample) |
| HU (1) | HUE061108T2 (enExample) |
| LT (1) | LT3298030T (enExample) |
| MX (1) | MX390894B (enExample) |
| PL (1) | PL3298030T3 (enExample) |
| RS (1) | RS64002B1 (enExample) |
| RU (2) | RU2754466C2 (enExample) |
| SG (1) | SG11201707426SA (enExample) |
| SI (1) | SI3298030T1 (enExample) |
| SM (1) | SMT202300026T1 (enExample) |
| WO (1) | WO2016184882A1 (enExample) |
| ZA (1) | ZA201706061B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| RU2736312C2 (ru) * | 2015-05-04 | 2020-11-13 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Белки, специфичные в отношении cd137 |
| KR20180029238A (ko) | 2015-07-15 | 2018-03-20 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3에 특이적인 신규 단백질 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3565843A1 (en) * | 2017-01-03 | 2019-11-13 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| WO2018134274A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| JP7312168B2 (ja) * | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| TW202003462A (zh) | 2018-03-26 | 2020-01-16 | 德商４Ｓｃ製藥公司 | 用於癌症療法的包括ｈｄａｃ抑制劑和ｃｄ１３７激動劑之組合 |
| HRP20230590T2 (hr) * | 2018-07-31 | 2024-02-16 | Pieris Pharmaceuticals Gmbh | Novi fuzijski protein specifičan za cd137 i pd-l1 |
| JP7476219B2 (ja) * | 2019-02-26 | 2024-04-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質 |
| KR20210146999A (ko) * | 2019-03-29 | 2021-12-06 | 피어이스 파마슈티컬즈 게엠베하 | 리포칼린 뮤테인의 흡입 투여 |
| EP3952996A1 (en) * | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
| KR20200124176A (ko) * | 2019-04-23 | 2020-11-02 | 주식회사 엘지화학 | 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드 |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| TWI862640B (zh) * | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN115960242B (zh) * | 2021-09-09 | 2023-10-17 | 广东东阳光药业股份有限公司 | 抗癌结合分子及其应用 |
| TW202428603A (zh) * | 2022-09-21 | 2024-07-16 | 美商思進公司 | 新穎的cd137及cd228特異性融合蛋白 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| WO1995031479A1 (en) | 1994-05-18 | 1995-11-23 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| TR200003635T2 (tr) | 1998-06-08 | 2001-04-20 | F.Hoffmann-La Roche Ag | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| AU2001294617A1 (en) | 2000-09-21 | 2002-04-02 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| CN104650213A (zh) | 2006-08-01 | 2015-05-27 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| ES2354653T3 (es) | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| JP5868593B2 (ja) | 2007-07-17 | 2016-02-24 | メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
| JP5848006B2 (ja) | 2007-10-19 | 2016-01-27 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | Ｎｇａｌの検出用イムノアッセイ及びキット |
| CA2729322C (en) | 2008-06-24 | 2020-05-26 | Technische Universitaet Muenchen | Muteins of hngal and related proteins with affinity for a given target |
| EP3660510A3 (en) | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| CA2808392C (en) | 2010-08-16 | 2020-03-10 | Pieris Pharmaceuticals Gmbh | Binding proteins for hepcidin |
| CN103221428B (zh) * | 2010-09-09 | 2016-02-10 | 辉瑞公司 | 4-1bb结合分子 |
| EP2640740B1 (en) | 2010-11-15 | 2017-03-15 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| WO2013174783A1 (en) | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| JP2016505826A (ja) * | 2012-12-10 | 2016-02-25 | フレッド ハッチンソン キャンサー リサーチ センター | スクリーニングの方法 |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| WO2015104406A2 (en) | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| ES2900898T3 (es) * | 2014-04-07 | 2022-03-18 | Chugai Pharmaceutical Co Ltd | Anticuerpos biespecíficos inmunoactivadores |
| AU2016212087B2 (en) | 2015-01-28 | 2019-11-07 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| BR112017017530A2 (pt) | 2015-02-18 | 2018-04-17 | Sanofi | proteínas específicas para pioverdina e pioquelina |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| RU2736312C2 (ru) * | 2015-05-04 | 2020-11-13 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Белки, специфичные в отношении cd137 |
| US10273275B2 (en) | 2015-05-18 | 2019-04-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-18 AU AU2016262845A patent/AU2016262845B2/en active Active
- 2016-05-18 RU RU2017135539A patent/RU2754466C2/ru active
- 2016-05-18 SI SI201631659T patent/SI3298030T1/sl unknown
- 2016-05-18 KR KR1020177035641A patent/KR102685748B1/ko active Active
- 2016-05-18 FI FIEP16729794.4T patent/FI3298030T3/fi active
- 2016-05-18 JP JP2017560331A patent/JP6947642B2/ja active Active
- 2016-05-18 HR HRP20230145TT patent/HRP20230145T1/hr unknown
- 2016-05-18 SM SM20230026T patent/SMT202300026T1/it unknown
- 2016-05-18 DK DK16729794.4T patent/DK3298030T5/da active
- 2016-05-18 CA CA2980838A patent/CA2980838A1/en active Pending
- 2016-05-18 SG SG11201707426SA patent/SG11201707426SA/en unknown
- 2016-05-18 PL PL16729794.4T patent/PL3298030T3/pl unknown
- 2016-05-18 HU HUE16729794A patent/HUE061108T2/hu unknown
- 2016-05-18 RS RS20230084A patent/RS64002B1/sr unknown
- 2016-05-18 ES ES16729794T patent/ES2938525T3/es active Active
- 2016-05-18 LT LTEPPCT/EP2016/061071T patent/LT3298030T/lt unknown
- 2016-05-18 EP EP16729794.4A patent/EP3298030B1/en active Active
- 2016-05-18 WO PCT/EP2016/061071 patent/WO2016184882A1/en not_active Ceased
- 2016-05-18 MX MX2017014716A patent/MX390894B/es unknown
- 2016-05-18 US US15/575,309 patent/US10913778B2/en active Active
- 2016-05-18 RU RU2021119777A patent/RU2021119777A/ru unknown
- 2016-05-18 CN CN201680028941.3A patent/CN108112253B/zh active Active
- 2016-05-18 EP EP22216061.6A patent/EP4219535A1/en active Pending
-
2017
- 2017-09-06 ZA ZA2017/06061A patent/ZA201706061B/en unknown
-
2021
- 2021-02-05 US US17/169,209 patent/US11919931B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519803A5 (enExample) | ||
| JP2018515085A5 (enExample) | ||
| JP2018526989A5 (enExample) | ||
| RU2017135539A (ru) | Слитый полипептид с противораковой активностью | |
| RU2017135596A (ru) | Слитый полипептид с противораковой активностью | |
| Linsley et al. | Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4): a disulfide-linked homodimer binds two CD86 molecules | |
| RU2018107991A (ru) | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 | |
| JP2017527272A5 (enExample) | ||
| JP2018515084A5 (enExample) | ||
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| RU2017135599A (ru) | Белки, специфичные в отношении cd137 | |
| FI3830120T3 (fi) | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini | |
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| CN114728040A (zh) | 新型白介素-2变体及其双功能融合分子 | |
| JP2015524799A5 (enExample) | ||
| JP2018532372A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| JP2019502694A (ja) | 二特異性抗体基幹 | |
| JP2017518748A5 (enExample) | ||
| EA012507B1 (ru) | Высокоаффинные мелан-а т-клеточные рецепторы | |
| JP2019506140A5 (enExample) | ||
| JP2019505565A5 (enExample) | ||
| Plaksin et al. | A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes | |
| JP2024507693A (ja) | 二重特異性抗体 | |
| KR20210091220A (ko) | 부착된 세포에 직접 신호를 보내지 않는 비-천연 nkg2d 수용체 |